Get the Stockscreener App
8.29
0.36%
-0.03
Pre-market:
8.49
0.20
+2.41%
Emergent Biosolutions Inc stock is traded at $8.29, with a volume of 688.68K.
It is down -0.36% in the last 24 hours and up +4.41% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
See More
Previous Close:
$8.32
Open:
$8.46
24h Volume:
688.68K
Relative Volume:
0.92
Market Cap:
$427.73M
Revenue:
$676.80M
Net Income/Loss:
$-8.60M
P/E Ratio:
-29.30
EPS:
-0.2829
Net Cash Flow:
$135.40M
1W Performance:
+3.62%
1M Performance:
+4.41%
6M Performance:
-32.77%
1Y Performance:
+32.64%
1-Day Range:
$8.23
$8.49
1-Week Range:
$7.56
$8.49
52-Week Range:
$5.615
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
8.29 | 427.73M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
[Form 4] Emergent BioSolutions Inc. Insider Trading Activity - Stock Titan
Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes - Stock Titan
Emergent BioSolutions (EBS) EVP uses 2,018 shares to cover RSU taxes - Stock Titan
Emergent BioSolutions (EBS) SVP reports 1,741-share tax withholding on RSU vesting - Stock Titan
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS) - Seeking Alpha
U.S. – Johnson & Johnson in charge of Baltimore vaccine facility - Digital Journal
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose - The Manila Times
Emergent (EBS) Q1 2026 Earnings Transcript - AOL.com
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Emergent BioSolutions (EBS) Consolidates Near Key Support After Flat SessionJurik MA - thelegaladvocate.com
Emergent BioSolutions (EBS) Secures $64.5M Contract Modification - GuruFocus
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)(Equine)] to Support U.S. Biodefense Strategy - The Manila Times
Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy - marketscreener.com
Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy - TradingView
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin ... - Caledonian Record
U.S. health agency awards $64.5M botulism antitoxin deal to Emergent - Stock Titan
EBS Technical Analysis | Trend, Signals & Chart Patterns | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
EBS Stock Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks - Stock Titan
Emergent Biosolutions donates thousands of NARCAN Nasal Spray units across the U.S. since 2021 - Traders Union
Emergent BioSolutions (EBS) Secures ACAM2000 Approval in Saudi A - GuruFocus
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - marketscreener.com
Saudi Arabia approves smallpox and mpox vaccine for people at high risk - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Stock Quote - The Chronicle-Journal
Global governments turn to Emergent Biosolutions for crisis health preparedness - Traders Union
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Common Stock (NY: EBS - FinancialContent
SABS: SAB-142 progresses in phase II-B with robust funding and regulatory clarity, targeting type 1 diabetes - TradingView
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance - MSN
Emergent BioSolutions Inc. (EBS): Investor Outlook with a Promising 31.43% Potential Upside - DirectorsTalk Interviews
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Harsanyi Zsolt - Moomoo
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
MSN Money - MSN
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Fowler Neal Franklin - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Zoon Kathryn C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Richard Ronald - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director FOWLER JOHN D JR - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director White Marvin L - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director DeGolyer Donald W - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Dayal Sujata Tyagi - Moomoo
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):